Pfizer Incorporated (NYSE: PFE) is a pharmaceutical company, ranking number one in sales in the world. The company is based in New York City, with its research headquarters in Groton, Connecticut. It produces Lipitor (atorvastatin, used to lower blood cholesterol); the neuropathic pain/fibromyalgia drug Lyrica (pregabalin); the oral antifungal medication Diflucan (fluconazole), the antibiotic Zithromax (azithromycin), Viagra (sildenafil) for erectile dysfunction, and the anti-inflammatory Celebrex (celecoxib) (also known as Celebra in some countries outside the USA and Canada, mainly in South America). Its headquarters are in Midtown Manhattan, New York City.
Some of this data may be out of date
State influence data from the National Institute on Money in State Politics changed in format and availability during the 2013-2014 election cycle. While we work to integrate their new style of data release, state-level campaign finance data for the 2014 cycle and beyond will be unavailable. We apologize for the inconvenience, but heartily recommend trying out their snazzy new site at FollowTheMoney.org!
Campaign Finance$44,634,924 Given
Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
state-level data is not available in bulk for 2014. for current state data, browse http://followthemoney.org/
- PAC Color Block
- Organization's PAC(s)
- Employee Color Block
- Associated Individuals
Republicans vs. Democratsin dollars. "Other" includes 3rd parties and organizations without official party affiliation.
State vs. Federalin dollars
Top PAC Recipients
- PAC Color Block
- Organization's PAC(s)
- Employee Color Block
- Associated Individuals
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying on Behalf of Pfizer Inc
Names of Lobbyists
Firm Hired Amount Pfizer Inc $140,520,000 Wyeth $2,459,268 Warner-Lambert $2,240,000 Zoetis Inc $1,880,000
Most Frequently Disclosed Lobbying Issues
- Health Issues,
- Medicare & Medicaid,
- Copyright, Patent & Trademark,
- Fed Budget & Appropriations,
- Consumer Product Safety,
Most Frequently Disclosed Bills
Bill No. Title H.R.1548 Pathway for Biosimilars Act H.R.1427 Promoting Innovation and Access to Life-Saving Medicine Act H.R.3200 America's Affordable Health Choices Act of 2009 S.301 Physician Payments Sunshine Act of 2009 H.R.1 American Recovery and Reinvestment Act of 2009 H.R.3590 Service Members Home Ownership Tax Act of 2009 H.R.965 Preservation of Antibiotics for Medical Treatment Act of 2011 S.726 Promoting Innovation and Access to Life-Saving Medicine Act S.501 Fair Prescription Drug Competition Act S.1082 Medical Device User Fee Amendments of 2007
RegulationsMentioned in 1902 dockets; Submitted to 228 dockets
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "Pfizer Inc" in public comments on proposed federal regulations.
Documents Submitted by the Organization
View all submissions data for Pfizer Inc
- Toggle 5 FDA Modify ANDA Suitability Petition Processing Practices 1993
- Toggle 4 SEC Comments on Proposed Rule: Security Holder Director Nominations 2003
- Toggle 3 SEC Comments on Proposed Rule: Strengthening the Commission's Requirements Regarding Auditor Independence 2002
- Toggle 3 FDA Standards for Standardized Numerical Identifier, Track and Trace, and Authentication for Prescription Drugs 2008
- Toggle 3 SEC Comments on Proposed Rule: Facilitating Shareholder Director Nominations 2009
- Toggle 3 FDA Take the Actions Described (1) Refuse to Approve any ANDA Referencing Lyrica That Contains an Isomeric Impurity Specification That Includes a “Not Less Than” Minimum Level or Otherwise Requires the Generic Product Covered by the ANDA to Contain an Isomeric Impurity.... 2012
- Toggle 2 FDA Biologics Price Competition and Innovation Act of 2009; Options for a User Fee Program for Biosimilar and Interchangeable Biological Product Applications for Fiscal Years 2013 through 2017; Request for Comments 2011
- Toggle 2 FDA Agency Information Collection Activities; Proposed Collection; Comment Request; FDA Survey of Physicians Perceptions of the Impact of Early Risk Communication about Medical Products 2006
- Toggle 2 FDA Good Laboratory Practice for Nonclinical Laboratory Studies 2010
- Toggle 2 SEC Comments on Proposed Rule: Implementation of Standards of Professional Conduct for Attorneys 2002
Mentions in Document Text
View all mentions data for Pfizer Inc
- Toggle 103 FDA Bulk Drug Substances That May Be Used to Compound Drug Products in Accordance With Section 503B of the Federal Food, Drug, and Cosmetic Act, Concerning Outsourcing Facilities; Request for Nominations 2013
- Toggle 67 FDA Deeming Tobacco Products To Be Subject to the Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Regulations on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products 2014
- Toggle 35 DOT 2007 U.S.-China Frequency Allocation Proceeding 2006
- Toggle 24 FDA Amlodipine Abbreviated New Drug Application Approvals 2007
- Toggle 24 FDA Modify ANDA Suitability Petition Processing Practices 1993
- Toggle 22 FDA NADA/ANADA Notices 2010
- Toggle 22 SEC Comments on Proposed Rule: Disclosure Regarding Nominating Committee Functions and Communications between Security Holders and Boards of Directors 2003
- Toggle 21 EPA Criteria and Standards for Cooling Water Intake Structures 2008
- Toggle 20 FDA Generic Drug Speeches & Policy and Procedure Guides 1990
- Toggle 19 FDA Docket Pertains to NADA/ANADA Notices 2008
Federal Spending28 contracts
Federal grants, contracts and loans are reported by federal agencies using the FPDS and FAADS systems. The data is made available to the public at USASpending.gov. Please note that the completeness and quality of the data varies greatly by agency.
Only grants, contracts and loans with amounts over $1 million are shown.
Because company names are not reported in a standardized manner, we cannot reliably determine the company receiving the contract or award. The results shown here are based on a search for the company name. Individual records may be missed or erroneously included because of name variations. For more information, please see our federal spending methodology page.
Note: Company names in federal spending data are not standardized. The table below is included only as a sample of what is available in the data and has not been reviewed for accuracy or completeness. To investigate the data further, use the links at the bottom of the table.
|Pfizer Inc.||2012||Centers For Disease Control||PFIZER VFC 2011||$287,552,818|
|Pfizer Inc.||2011||Centers For Disease Control||VACCINE FOR CHILDREN 2011||$281,640,506|
|Pfizer Inc.||2013||Centers For Disease Control||VACCINE FOR CHILDREN 2013||$280,450,984|
|Pfizer Inc.||2012||Centers For Disease Control||VFC 2012||$272,238,691|
|Pfizer Inc.||2012||Centers For Disease Control||VFC 2012||$230,002,760|
|Pfizer Inc.||2013||Centers For Disease Control||VFC 2012||$153,876,953|
|Pfizer Inc.||2012||Centers For Disease Control||VFC 2012||$140,041,787|
|Pfizer Inc.||2012||Centers For Disease Control||PFIZER VFC 2011||$131,240,596|
|Pfizer Inc.||2011||Centers For Disease Control||PFIZER VFC 2011||$111,038,414|
|Pfizer Inc.||2011||Centers For Disease Control||VACCINE FOR CHILDREN 2011||$103,135,727|
Contractor Misconduct11 Instances
This information is collected by the Project On Government Oversight from press releases, court documents, news reports and other public records. It is not meant to be an exhaustive account of all instances of federal contractor misconduct.
More information on each instance, including primary source documents, is available on POGO's site by clicking on the instance description. More information on POGO's methodology is available here.
|Misconduct Type||Hired By||Incident||Year||Disposition||Penalty|
|Health||None||Illegal Marketing of Bextra and Other Drugs||2009||Pleaded Guilty||$2,300,000,000|
|Government Contract Fraud||Health and Human Servs.||Sandler et al. v. Wyeth Pharmaceuticals||2005||Settlement||$491,000,000|
|Health||None||Illegal Marketing of Neurontin||2004||Pleaded Guilty||$430,000,000|
|Health||None||Illegal Testing in Nigeria||2009||Settlement||$75,000,000|
|Government Contract Fraud||Multiple Agencies||Lipitor False Claims||2002||Settlement||$49,000,000|
|Health||None||Illegal Marketing of Genotropin||2007||Pleaded Guilty||$34,700,000|
|Health||None||U.S. ex rel. Wetherholt and Drimer v. Pfizer (Illegal Marketing of Detrol)||2011||Settlement||$14,500,000|
|Antitrust||None||Hawaii Average Wholesale Price Litigation||2010||Settlement||$8,200,000|
|Labor||None||McClain v. Pfizer (Whistleblower Retaliation)||2007||Judgment Against Defendant||$1,370,000|
|Health||None||Lipitor Webpage Misbranding||2011||Investigative Finding||$0|
|Health||None||FDA Inspection of New York City Facility||2010||Investigative Finding||$0|
EPA Violations20 Enforcement Actions
Figures are based on data from the Environmental Protection Agency’s ECHO website. The ECHO database contains federal and state environmental enforcement actions. Data displayed here includes only those actions that began after 2000 and resulted in fines of over $1 million.
Actions where the company was the sole defendant are listed first. Actions where the company is one of multiple defendants are listed subsequently.
For more information see our EPA methodology page.
|Pharmacia Corporation (Industri-Plex Site)||Pharmacia Corporation (+1 others)||2008||Woburn, Ma||$37,245,000|
|Alliance Chemical Inc Et Al.||Pharmacia Corp fka Monsanto Company (+71 others)||2007||Newark, Nj||$37,000,000|
|Sauget Area 2 Unilateral Admin Order (Cercla)||Pharmacia Corp (+76 others)||2002||Sauget, Il||$26,500,000|
|Pharmacia Corporation/ Industri-Plex Site Ou-2||Pharmacia Corporation (+1 others)||2007||Woburn, Ma||$25,600,000|
|Air Products & Chemical, Inc Et Al||Pharmacia Corporation (+40 others)||2005||Elkton, Md||$24,500,000|
|3m Company||Warner-Lambert Company LLC (+106 others)||2008||Wood Ridge, Nj||$18,000,000|
|Alcan Corporation||Pharmacia Corporation f/k/a Monsanto Company (+81 others)||2007||Newark, Nj||$13,150,000|
|Casmalia - De Minimis Aoc||Pfizer Inc. (+191 others)||2004||Casmalia, Ca||$11,900,000|
|Agere Systems, Et Al||Pharmacia Corporation/Monsanto (+138 others)||2007||Elkton, Md||$11,300,000|
|Anniston Pcb Site||Pharmacia Corporation (+2 others)||2003||Anniston, Al||$11,218,346|
Advisory Committees58 people on 48 committees
Data is based on disclosures required by the Federal Advisory Committee Act (FACA). Matches are based on the occurrence of the company name in the committee member affiliation. Variations in company names may cause some matches to be missed.
The table shows only the top 10 agencies. To search and download raw records from the complete dataset see the FACA data section.
Table shows employees of "Pfizer Inc" that sat on federal advisory committees.
- Toggle Department of Health and Human Services 33 people on 26 committees
- Toggle National Science Foundation 6 people on 6 committees
- Toggle Department of Commerce 4 people on 5 committees
- Toggle Department of Veterans Affairs 2 people on 2 committees
- Toggle Department of Labor 4 people on 2 committees
- Toggle Department of State 4 people on 2 committees
- Toggle Environmental Protection Agency 2 people on 1 committee
- Toggle Department of Defense 2 people on 2 committees
- Toggle Department of Homeland Security 2 people on 2 committees